21 completed, 11 terminated, 5 recruiting, 2 active not recruiting. 42 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 42 | Completed 21, Terminated 11, Recruiting 5, Active not recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 7, Recruiting 2, Terminated 2 |
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 486 | 2027-01-01 | 2026-09-17 |
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy 3-N-butylphthalide - Multiple System Atrophy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2026-08-27 | 2026-10-16 |
| Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome Cold Stress, Maximal Dynamic Exercise, Isometric Handgrip Exercise with Post-Exercise Muscle Ischemia - Down Syndrome, Autonomic Dysfunction | Phase 3 | Recruiting | University of Colorado, Denver | 200 | 2026-04-06 | 2026-10-13 |
| MSA-01 in Multiple System Atrophy MSA-01, Placebo - Multiple System Atrophy (MSA) | Phase 3 | Recruiting | Tokyo University | 140 | 2026-02-09 | 2026-03-04 |
| A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) Amlenetug, Placebo - Multiple System Atrophy | Phase 3 | Active not recruiting | H. Lundbeck A/S | 401 | 2024-12-03 | 2026-10-14 |
| [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT - Parkinson Disease, Dementia With Lewy Bodies | Phase 2 / Phase 3 | Recruiting | prof. dr. Koen Van Laere | 113 | 2024-01-19 | 2025-02-06 |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy Ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | Active not recruiting | Theravance Biopharma | 102 | 2023-06-27 | 2025-09-05 |
| Study of Atomoxetine in the Prevention of Vasovagal Syncope Atomoxetine Hydrochloride, Placebo - Vasovagal Syncope | Phase 3 | Recruiting | University of Calgary | 180 | 2022-06-01 | 2024-05-09 |
| Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease Autonomic testing on and off levodopa - Parkinson Disease, Orthostatic Hypotension | Phase 2 / Phase 3 | Completed | University of Utah | 40 | 2022-05-11 | 2024-12-05 |
| Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo Buspirone, Placebo - Vertigo, Autonomic Dysfunction | Phase 3 | Completed | Valenta Pharm JSC | 268 | 2022-01-28 | 2022-06-24 |
| A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS Albumin (Human) 5%, USP, Normal Saline 0.9% Infusion Solution Bag - Postural Orthostatic Tachycardia Syndrome | Phase 3 | Withdrawn | University of Alberta | 2022-01-01 | 2024-09-19 | |
| Midodrine and Fludrocortisone for Vasovagal Syncope Midodrine Hydrochloride Tablets, Fludrocortisone Acetate Tablets, Lifestyle modification - Syncope, Vasovagal | Phase 3 | Unknown | Tehran Heart Center | 1375 | 2020-11-19 | 2021-04-19 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Terminated | Theravance Biopharma | 110 | 2019-09-19 | 2022-11-30 |
| Study of BHV-3241 in Participants With Multiple System Atrophy Verdiperstat, Placebo - Multiple System Atrophy | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 421 | 2019-07-29 | 2023-09-29 |
| Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy Tllsh2910, Placebo - Ataxia, Cerebellar, Multiple System Atrophy | Phase 3 | Terminated | National Taiwan University Hospital | 18 | 2019-04-02 | 2023-04-07 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA | Phase 3 | Terminated | Theravance Biopharma | 203 | 2019-02-22 | 2023-01-20 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
| Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Ivabradine, Placebo - Postural Orthostatic Tachycardia Syndrome | Phase 3 | Completed | University of California, San Diego | 37 | 2018-02-06 | 2021-06-29 |
| Treatment of Post-SCI Hypotension Midodrine Hydrochloride - Spinal Cord Injury, Autonomic Dysreflexia | Phase 2 / Phase 3 | Completed | James J. Peters Veterans Affairs Medical Center | 66 | 2017-06-01 | 2025-02-21 |
Showing 20 of 42. Sign in to see all of them.
Hypotension, Orthostatic (15) · Multiple System Atrophy (15) · Parkinson Disease (9) · Pure Autonomic Failure (8) · Hypotension (6) · Dizziness (5) · Parkinsonian Disorders (5) · Syncope (5) · dopamine beta hydroxylase deficiency (5) · Spinal Cord Injuries (4) · Orthostatic Intolerance (3) · Postural Orthostatic Tachycardia Syndrome (3) · Syncope, Vasovagal (3) · Autonomic Nervous System Diseases (2)
Nervous System Diseases (42) · Autonomic Nervous System Diseases (40) · Central Nervous System Diseases (26) · Basal Ganglia Diseases (22) · Brain Diseases (22) · Neurodegenerative Diseases (22) · Synucleinopathies (21) · Cardiovascular Diseases (20) · Movement Disorders (20) · Orthostatic Intolerance (19) · Vascular Diseases (19) · Neurologic Manifestations (18) · Pathological Conditions, Signs and Symptoms (18) · Signs and Symptoms (17)
Droxidopa (8) · ampreloxetine (4) · Midodrine (3) · Carbidopa (2) · Mannitol (2) · Sodium Chloride (2) · 3-n-butylphthalide (1) · Albumins (1) · Albuterol (1) · Atomoxetine Hydrochloride (1) · Buspirone (1) · Cold-Shock Response (1) · Curcumin (1) · Deferasirox (1) · Docosahexaenoic Acids (1)
Chelsea Therapeutics (5) · Theravance Biopharma (4) · James J. Peters Veterans Affairs Medical Center (2) · NYU Langone Health (2) · Vanderbilt University (2) · Beth Israel Deaconess Medical Center (1) · Biohaven Pharmaceuticals, Inc. (1) · Brock University (1) · Children's Hospital Los Angeles (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dr. Johannes Levin (1) · Florida Atlantic University (1) · GE Healthcare (1) · H. Lundbeck A/S (1) · King's College London (1)
United States (24) · Canada (10) · Australia (7) · France (7) · Germany (7) · United Kingdom (7) · Italy (6) · New Zealand (6) · Austria (5) · Denmark (5) · Spain (5) · Estonia (4) · Israel (4) · Poland (4) · Portugal (4)
David Robertson, MD (2) · Phillip A Low, MD (2) · Roy Freeman, MD (2) · Alberto Vasquez, MD (1) · Alfredo J Gamboa, MD (1) · Alvin McElveen, MD (1) · Arash Jalali, PhD (1) · Arya Aminorroaya, MD, MPH (1) · Betty Tuller, PhD (1) · Brent Goodman, MD (1) · Christopher J Mathias, MD (1) · Christopher J. Mathias, MD (1) · Chun-Hwei Tai (1)
PMID 27538531, PMID 28494751, PMID 42475649, PMID 17385265, PMID 17951266, PMID 17965289, PMID 19029129, PMID 19651280, PMID 19771175, PMID 21062792, PMID 21386111, PMID 21762873, PMID 21829612, PMID 22174345, PMID 23700789, PMID 24326693, PMID 24507091, PMID 25350981, PMID 26241226, PMID 26545369, PMID 29573263, PMID 30003579, PMID 31278067, PMID 32203065, PMID 33177997, PMID 34115419, PMID 35366432, PMID 37100187, PMID 38712567, PMID 40924149, PMID 41269291
2018 (2), U54NS065736 (2), 2015 (1), 2019 (1), P01HL056693 (1), P01NS044233 (1), T32AG000279 (1)